Specialty
Cataract & Refractive Dermatology General Ophthalmology Glaucoma Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Login

Individualized Management of Patients With Glaucoma: How Therapeutic Advances Will Improve Patient Care Web 1

By: Thomas Samuelson, MD; Douglas Rhee, MD

Webinar Credits: 1

Expiration Date: Tuesday, June 25, 2019
Release Date: June 26, 2018

Learning Objectives

Learning Objectives
Upon completion of this activity, the participant should be able to:

Discuss the chemical structure and mechanism of action of topical glaucoma medications and evolving neuroprotective medications
Explain the anti-fibrotic activity in novel drug classes
Evaluate novel therapeutics and classes of drugs and their potential for enhanced patient compliance

Accreditation and Designation Statement

Accreditation Statement

Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

 Credit Designation Statement

Evolve Medical Education designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Evolve is an approved COPE Administrator.

This course is COPE approved for 1.0 hours of CE Credit for Optometrists

COPE Course ID: 58456-GL

COPE Event ID: 115763

Faculty and Disclosures

 

Thomas Samuelson, MD

Minnesota Eye Consultants
Adjunct Professor University of Minnesota
Minneapolis, MN

Douglas Rhee, MD
Case Western Reserve University
Department Chair
University Hospitals
Department of Ophthalmology and Visual Sciences
Cleveland, Ohio

The following faculty/staff members have the following financial relationships with commercial interests:

Thomas Samuelson, MD; has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: AcuMEMS; Aerie Pharmaceuticals; Akorn; Alcon Surgical; AMO (Abbott Medical Optics) AqueSys; Bausch and Lomb; BELKIN Laser; Endo Optics; Equinox; Glaukos Corporation; and Ivantis; Ocular Surgery News; PolyActiva, Santen Pharmaceutical Co, Ltd; Shire Plc; Transcend Medical, Veracity Innovations, LLC; and Vindico/Slack. Stock Options: Equinox; Glaukos Corporation; and Ivantis.

Douglas Rhee, MD; has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant:  Aerie Pharmaceuticals. Speakers Bureau:  Bausch and Lomb; Grant/Research Support:  Allergan plc, Glaukos Corporation, and Ivantis.

Disclaimer

Off-Label Statement
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve,  or Aerie Pharmaceuticals.

Pretest

  • a. 1b. 2c. 3d. 4e. 5
  • a. 1b. 2c. 3d. 4e. 5

Video Resources

Next

Test

Instructions

Step 1 of 3

33%
  • AgreeNeutralDisagree
    • Discuss the chemical structure and mechanism of action of topical glaucoma medications and evolving neuroprotective medications
    • Explain the anti-fibrotic activity in novel drug classes
    • Evaluate novel therapeutics and classes of drugs and their potential for enhanced patient compliance
Back